Balyasny Asset Management
SURF

Balyasny Asset Management’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Balyasny Asset Management’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,632
Closed -$11K – 3367
2022
Q3 		$11K Buy
+10,632
New +$17K ﹤0.01% 2645

Other funds holding SURF

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Balyasny Asset Management's SURF Position: Q4 2022 in Review

Balyasny Asset Management sold out of Surface Oncology, Inc. Common Stock (SURF) in Q4 2022, closing a stake of 10,632 shares — an estimated $11K sold.

Balyasny Asset Management first reported a position in SURF in Q3 2022 and held it in 1 quarter. The position peaked at $11K in Q3 2022. 79 funds tracked by Wall St. Rank hold SURF as of Q4 2022.

  • Balyasny Asset Management reported no remaining Surface Oncology, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 10,632 Surface Oncology, Inc. Common Stock shares in Q4 2022, an estimated $11K.
  • Balyasny Asset Management first reported a position in Surface Oncology, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Surface Oncology, Inc. Common Stock position peaked at $11K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.